Letrozole Hutech Labs
€150.00
General introduction and principle of operation Letrozole Hutech Labs
Letrozole Hutech Labs is an advanced non-steroidal aromatase inhibitor primarily used for the management of estrogen-receptor positive breast cancer in postmenopausal women. Its primary function is to inhibit the aromatase enzyme, which plays a critical role in the conversion of androgens to estrogens. By suppressing estrogen levels in the body, Letrozole can effectively slow or reverse the growth of estrogen-sensitive tumors.
This medication is also utilized in various other applications within the realm of hormone regulation, including off-label uses among athletes and bodybuilders aiming to control estrogen levels during performance-enhancing cycles. With a half-life of approximately two days, Letrozole provides sustained action, requiring daily dosage for optimal results.
Main components and active substances
The efficacy of Letrozole Hutech Labs is rooted in its active ingredient, letrozole, which operates through specific biochemical interactions. Understanding its components helps illuminate its benefits and potential implications in various treatment scenarios.
- Active Substance: Letrozole is the cornerstone of this medication, targeting estrogen production.
- Chemical Name: 4,4′-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile is the formal designation, highlighting its complex structure.
- Storage Conditions: It is essential to store at room temperature, away from moisture and heat to maintain efficacy.
- Formulation: Available as oral tablets, each containing a measured dosage of Letrozole for precise administration.
- Packaging: Comes in sachets, typically containing 100 tabs, ensuring convenience and extensive treatment options.
Mechanisms of action and expected results
Letrozole functions by competitively inhibiting the aromatase enzyme, crucial for estrogen synthesis. This mechanism leads to a significant reduction in circulating estrogen levels, which is vital for conditions driven by estrogen sensitivity. Consequently, this reduction yields several expected therapeutic effects.
- Estrogen Reduction: Lower estrogen levels prevent the stimulation of estrogen-sensitive tumors.
- Increased LH and FSH: Letrozole induces an increase in luteinizing hormone and follicle-stimulating hormone, supporting various hormonal pathways.
- Bone Health Monitoring: Due to potential osteoporosis risk from long-term use, monitoring bone density is critical.
Recommendations for use
For optimal results, users should adhere to specific guidelines when utilizing Letrozole. These recommendations are crucial for maximizing the therapeutic benefits while minimizing potential risks. Proper dosing is integral depending on the individual’s medical needs and therapeutic aims.
- Dosage: The medical dosage typically ranges from 2.5 mg daily, while athletes may use lower dosages from 0.5 mg to 2.5 mg.
- Scheduled Monitoring: Regular lab tests are advised to keep track of liver function and lipid profiles during treatment.
- Professional Supervision: Always consult with a healthcare professional before beginning treatment to ensure personalized guidelines are followed.
Possible risks and contraindications Letrozole Hutech Labs
While Letrozole Hutech Labs offers numerous benefits, it is essential to be aware of potential risks and contraindications associated with its use. Understanding these factors is crucial for ensuring safe administration.
- Side Effects: Possible adverse reactions include hot flashes, joint pain, and fatigue, which may impact quality of life.
- Osteoporosis Risk: Extended use can increase the risk of developing osteoporosis, necessitating regular bone density assessments.
- Blood Pressure Effects: It may lead to a decrease in blood pressure, especially in sensitive individuals.
| Active substance | Letrozole |
|---|---|
| Active Half-Life | 2 days |
| Classification | Non-steroidal aromatase inhibitor |
| Dosage | 0.5 – 2.5 mg/day |
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | Monitoring of liver function tests, lipid profiles, and bone density |
| Also known as | Letrozol |
| Blood pressure | Can cause a decrease in blood pressure |
| Trade name | Femara |
| FORM | Oral |
| Dosage Unit | Tabs |
| ean13 | 1392442098059 |
| Reference | SHTCH007 |
| Tab Piece | 100 Tabs |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile |
| Formula | C17H11N5 |
| Substance class | Aromatase inhibitor |
| Main action | Inhibits the enzyme aromatase, preventing the synthesis of estrogen |
| Half-life | 2 days |
| Dosage (medical) | 2.5 mg daily |
| Dosage (sports) | Typically 0.5 mg to 2.5 mg daily depending on purpose and cycling needs |
| Effects | Reduces estrogen levels, increases luteinizing hormone and follicle-stimulating hormone levels |
| Side effects | Hot flashes, joint pain, fatigue, increased risk of osteoporosis, nausea |
| Use in sports | Used by bodybuilders and athletes to reduce estrogen levels and increase testosterone levels |
| Packing | Sachet |
| 5 |
|
0 |
| 4 |
|
0 |
| 3 |
|
0 |
| 2 |
|
0 |
| 1 |
|
0 |



Reviews
There are no reviews yet.